Internal Medicine, Medical Oncology · Austin, TX
NPI
1003839820
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
6204 Balcones Dr
Austin, TX, 78731
Phone (512) 427-9400
Groups this clinician bills Medicare through
Medicare paid, 2024
$73K
1,574 services
Medicare patients, 2024
107
Average age 74
Drug cost, 2024
$1.9M
819 prescriptions
Company payments, 2025
$3,399
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Debra A Patt was code 80053 (clinical chemistry), 153 times for 63 patients. In total Debra A Patt billed 1,574 services in 52 codes, and Medicare paid $73K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 80053 Clinical Chemistry | Office | 153 | 63 | $10.12 | $1,549 |
| 36415 Venipuncture Blood Collection | Office | 152 | 67 | $8.44 | $1,283 |
| 85025 Blood Count | Office | 150 | 63 | $7.40 | $1,109 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 128 | 62 | $11.78 | $1,508 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 92 | 11 | $68.60 | $6,311 |
| 99214 Office E&M - Established | Office | 72 | 47 | $90.82 | $6,539 |
| 86300 Immunoassay | Office | 67 | 24 | $19.36 | $1,297 |
| 99215 Office E&M - Established | Office | 39 | 21 | $129.98 | $5,069 |
| A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 31 | 19 | $89.38 | $2,771 |
| 78815 PET- Oncology | Office | 29 | 17 | $1,235.69 | $36K |
| 99213 Office E&M - Established | Office | 19 | 17 | $72.43 | $1,376 |
By year: 2022 $1.8M for 116,736 services; 2023 $185K for 11,750 services; 2024 $73K for 1,574 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80053 Clinical Chemistry | 153 | 63 | $10.12 | $1,549 |
| 36415 Venipuncture Blood Collection | 152 | 67 | $8.44 | $1,283 |
| 85025 Blood Count | 150 | 63 | $7.40 | $1,109 |
| 86300 Immunoassay | 67 | 24 | $19.36 | $1,297 |
Medicare prescription drug claims, 2024
In 2024, the drug Debra A Patt prescribed most often to Medicare patients was Letrozole, with 381 prescriptions and refills. In total Debra A Patt wrote 819 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 381 | 828 | 100 | $6,940 |
| Tamoxifen Citrate Generic | 72 | 208 | 24 | $1,653 |
| Ibrance Palbociclib | 66 | 66 | Under 11 | $1.0M |
| Anastrozole Generic | 47 | 137 | 15 | $1,147 |
| Verzenio Abemaciclib | 24 | 24 | Under 11 | $272K |
| Dexamethasone Generic | 20 | 20 | Under 11 | $120 |
| Ondansetron Odt Ondansetron | 19 | 19 | 14 | $172 |
| Truqap Capivasertib | 18 | 18 | Under 11 | $405K |
| Exemestane Generic | 16 | 24 | Under 11 | $902 |
| Valacyclovir Valacyclovir Hcl | 13 | 13 | Under 11 | $236 |
| Prochlorperazine Maleate Generic | 12 | 12 | 12 | $147 |
Brand drugs: - claims; generic drugs: 678 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Debra A Patt $3,399 ($3,399 in general payments such as food, travel and fees) from 4 companies. The largest payer was Janssen Global Services, LLC with $2,618.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.